Protocol No
MERCK-MK1084-001
Phase
I
Summary
This project is being done to test the safety and tolerability of MK-1084 alone in combination with pembrolizumab in patients with solid tumor cancers that have a mutated KRAS gene.
Description
This project is being done to test the safety and tolerability of MK-1084 alone in combination with pembrolizumab in patients with solid tumor cancers that have a mutated KRAS gene.
Participating Institutions
Froedtert Hospital
Status
OPEN TO ACCRUAL
Categories
Cancer,
Colorectal,
Early Phase/Multiple Disease Site Cancers,
Thoracic Cancers,
Sarcoma,
Skin Cancers,
Prostate and Urologic Cancers,
Head and Neck Cancers,
Gynecologic Cancers,
Gastrointestinal Cancers,
Eye/Orbital Cancers,
Endocrine Cancers,
Breast Cancers,
Lung,
Esophagus,
Other Skin,
Melanoma, Skin,
Other Urologic,
Bladder,
Prostate,
Kidney,
Lip, Oral Cavity and Pharynx,
Larynx,
Other Gynecologic,
Uterine,
Ovary,
Cervix,
Other Gastrointestinal,
Stomach,
Pancreas/Liver,
Esophagus
ClinicalTrials.gov